Running title: Gastric PAI-1 expression in hypergastrinemia 
In gastric biopsies from subjects with elevated plasma gastrin, the abundances of PAI-1, uPA and uPAR mRNAs measured using qPCR, were increased compared to subjects with plasma concentrations in the reference range. In patients with hypergastrinemia due to autoimmune chronic atrophic gastritis, there was increased abundance of PAI-1, uPA and uPAR mRNAs that was reduced by octreotide or antrectomy. Immunohistochemistry revealed localisation of PAI-1 to parietal cells and ECL cells in micronodular neuroendocrine tumors in hypergastrinaemic subjects. Transcriptional mechanisms were studied using a PAI-1-luciferase promoter-reporter construct transfected into AGS-G R cells. There was time-and concentrationdependent increase of PAI-1-luciferase expression in response to gastrin that was reversed by inhibitors of the PKC and MAPK pathways. In Boyden chamber assays, recombinant PAI-1 inhibited gastrin-stimulated AGS-G R cell migration and invasion, and siRNA treatment increased responses to gastrin.
We conclude that elevated plasma gastrin concentrations are associated with increased expression of gastric PAI-1 which may act to restrain gastrinstimulated cell migration and invasion.
(213 words) In addition to its well known roles in stimulating gastric acid secretion and gastric epithelial cell proliferation, the gastric hormone gastrin also regulates the expression of a variety of genes that appear to be involved in control of mucosal organisation (7). These include both matrix metalloproteinases (MMP) such as MMP-7 and MMP-9, and serine protease inhibitors including tissue inhibitors of matrix metalloproteinases (TIMPS) and plasminogen inhibitor (PAI)-2 (33; 34; 38; 39). The latter is part of the urokinase plasminogen activator (uPA) system that in many tissues is associated with thrombolysis, fibrosis, tissue remodelling and the progression to cancer. This system consists of the serine proteinase uPA which converts plasminogen to plasmin, several plasminogen activator inhibitors (PAI-1, -2, and -3), and the uPA receptor (uPAR) which binds uPA at the advancing edge of migrating cells (30). In addition to activation of plasmin and consequent degradation of fibrin, uPA is associated with degradation of extracellular matrix, stimulation of angiogenesis, mitogenesis, cell migration and adhesion. The mechanisms controlling the expression of different members of the uPA system in gastric mucosa are still far from clear.
Recent studies have indicated that Helicobacter pylori infection is associated
with increased expression of PAI-2 and other members of the uPA system in gastric mucosa (18; 19; 35) . Members of the uPA system are also expressed in gastric cancer and there is evidence that they are associated with poor clinical outcome in these tumours, as well as others (9; 11; 16; 23; 24).
Together these observations suggest that the uPA system might have a role in controlling gastric mucosal organisation and function. Nørsett et al., page 4 Gastric neuroendocrine tumours may arise as a consequence of transformation of enterochromaffin-like (ECL) cells on a background of elevated plasma gastrin concentrations secondary to autoimmune atrophic gastritis leading to destruction of parietal cells, pernicious anemia (PA) and profound hypochlorhydria, or as a consequence of gastrinoma particularly in the multiple endocrine neoplasia (MEN)-1 syndrome (4; 5; 10). Although the association of some gastric neuroendocrine tumors with hypergastrinemia is well recognized, the mechanisms by which gastrin determines tumor progression are not well understood. A previous study noted that gastrin treatment of AGS-G R cells increased the abundance of PAI-1 detected in DNA arrays, and more recently uPA was shown to be upregulated in patients treated with the acid inhibitor esomeprazole who exhibited hypergastrinemia (25; 33). In the present study, we asked whether there was up-regulation of members of the uPA system in hypergastrinemia and examined the consequences for cell migration and invasion in the case of PAI-1.
MATERIALS AND METHODS
Cells, plasmids and reagents. AGS-G R cells were maintained as previously published (36). A plasmid encoding 4.5 kb of the human PAI-1 promoter coupled to luciferase (PAI-1-luc) was generated as previously reported (19).
Gastrin-17 was obtained from Bachem (St Helens, Merseyside, UK). Phorbol-12-myristate-13-acetate (PMA) was obtained from Sigma (Poole, Dorset, UK); LY294002, PD98059, and U0126 were obtained from Promega (Southampton, UK). Human recombinant PAI-1 and Ro-32-0432 were obtained from Calbiochem (Nottingham, UK). Small interfering RNA (siRNA) for PAI-1 and control scrambled oligonucleotides were obtained from Santa Cruz (Santa Cruz, CA, US). Other chemicals were obtained from Sigma (Poole, Dorset, UK).
Patients. Endoscopic pinch biopsies were obtained from dyspeptic patients with normal endoscopy. Two antral biopsies were taken for urease test and 2 -4 antral and 2 -4 corpus biopsies were taken for histology; an additional 6 corpus biopsies were taken for RNA extraction. The present studies describe patients that were H.pylori negative by serology, antral urease test and antral and corpus histology. Some patients were on proton pump inhibitors and these were discontinued one week before gastroscopy. On the basis of plasma gastrin concentrations, 16 subjects were selected with gastrin <30 pM (upper limit of the reference range) and 12 with gastrin >30 pM. In the former group 8 had been on PPIs and in the latter 6. In addition biopsies were taken from ten patients with PA. Five patients with PA who exhibited macroscopic ECL cell neuroendocrine tumours were subjected to octreotide (25 μg/h) suppression test for 72 h and based on their response underwent antrectomy (13) . Gastric biopsies were obtained at endoscopy before and immediately after octreotide, and before and 12 months after antrectomy. In patients with macroscopic ECL cell nodules, the biopsies used for this study were taken from adjacent mucosa. The study was approved by the Ethics Committees of the Royal Liverpool and Broadgreen and Aintree University Hospitals NHS Trusts. All patients gave informed consent. Gastrin radioimmunoassay. Plasma samples were assayed for total amidated gastrin concentrations by radioimmunoassay using antibody L2 which reacts at the C-terminus of G17 and measures G17, G34 and minor components such as G14 with similar affinity (8).
Immunohistochemistry. Formalin-fixed, paraffin-embedded tissue sections were processed for immunohistochemical detection of PAI-1 (American Diagnostica Inc. Greenwich, CT, USA), chromogranin A (Dako UK Ltd, Ely, UK) and synaptophysin (Leica Microsystems, Milton Keynes, UK) as previously described (19). In control sections, the primary antibody was omitted.
Luciferase promoter-reporter assays. Gastric glands were prepared from gastroscopic biopsies of control subjects as previously described (38) and transfected with PAI-1-luc according to the method used previously (19). and HyperFilm (Amersham) as previously described (22). Samples were reprobed for GAPDH (Biodesign, Saco, Maine, USA).
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Statistics.
Results are presented as mean ± SE; comparisons were made by Student's t-test or Anova as appropriate and were considered significant at P < 0.05.
RESULTS
Increased gastric PAI-1 in hypergastrinemia.
In subjects with plasma gastrin concentrations that exceeded the reference range (>30pM), PAI-1 mRNA abundance was increased approximately 2-fold compared to subjects with plasma concentrations within the reference range (Fig. 1A ,B). These subjects were H. pylori negative and so the increase was not attributable to
Helicobacter infection which has previously been associated with increased expression of members of the uPA system (19). Because PAI-1 interacts with both uPA and uPAR we also analysed these in the same samples, and in both cases there were increases suggesting that the system as a whole was
To further explore the idea that increased gastrin might control expression of this system, we then examined mRNA abundance of PAI-1 in patients with hypergastrinemia due to chronic atrophic gastritis. Circulating gastrin in these patients was typically 10 to 100-fold elevated compared with normal subjects, and PAI-1 mRNA abundance was elevated approximately 10-fold (Fig. 1C,D) .
Again, there were also significant increases in uPA and uPAR mRNA (Fig. 1D) .
Decreased gastric PAI-1 mRNA after octreotide or antrectomy. In PA patients with ECL cell neuroendocrine nodules, 3-day infusion of octreotide was employed to establish suitability for subsequent antrectomy as previously described (13) . After octreotide, there was decreased plasma gastrin. In biopsies taken from corpus mucosa that did not include ECL cell nodules, there was also decreased HDC mRNA abundance used as a marker for ECL cell function ( Fig. 2A,B ). In addition, octreotide was associated with a decrease of approximately 70% in PAI-1 mRNA in these biopsies and with a significant but slightly smaller decrease in uPA mRNA, compatible with acute endocrine regulation of these transcripts (Fig. 2C,D) . Moreover, 12 months after antrectomy, plasma gastrin was reduced to concentrations within or close to the reference range and HDC mRNA was also significantly reduced ( Fig. 2A,B ). In these circumstances there was a 70% reduction in PAI-1 mRNA abundance (Fig. 2D ). There was also decreased abundance of uPA mRNA which although statistically significant was less than that seen for PAI-1 and HDC mRNAs (Fig. 2C ).
Cellular localisation of PAI-1. In immunohistochemistry, PAI-1 was found to be localised to parietal cells in hypergastrinemic patients without chronic atrophy confirming the localisation reported previously (Fig. 3A) (19). In PA patients with micronodular ECL cell tumors, there was clear localisation of PAI-1 to ECL cell micronodules (Fig. 3B) , characterised by chromogranin A and synaptophysin staining (Fig. 3C,D) . In addition, weak staining for PAI-1 was observed in the stroma (Fig. 3B ) but staining in control sections was negative (Fig. 3E) . induced a concentration dependent increase in luciferase expression over the range 0.3 to 10 nM that was maximal 6 h after stimulation (Fig. 4A,B) . The response to 1nM gastrin was inhibited by Ro-32-0432 which is an inhibitor of PKC; moreover, stimulation of PKC with PMA produced a robust increase in PAI-1-luc expression that was inhibited by Ro-32-0432 (Fig. 4C,D) . In addition, the response to both gastrin and PMA was partially reversed by U0126, which inhibits the activation of MAPkinasekinase (MEK)-1 and -2 ( inhibitor LY204002 had no effect on PAI-1-Luc expression (Fig. 4C) .
Gastrin increases PAI-1-luc expression via Protein
PAI-1 inhibits AGS-G R cell migration and invasion.
Since the uPA system is implicated in control of cell migration and invasion we examined the role of the system on G17-stimulated migration and invasion of AGS-G R cells in Boyden chambers. There was stimulation of AGS-G R cell migration and invasion in response to G17 as previously noted (35); in the presence of PAI-1 (40nM) the migration and invasion responses to G17 were 56.6 ± 11.3 % and 34.3 ± 1.7 %, respectively, of those to G17 alone (p<0.05 in both cases). We considered the possibility that induction of PAI-1 might also influence gastrin stimulated cell adhesion (26); however, while acute treatment of AGS-G R cells with 1 nM G17 increased adhesion in a dose-dependent manner, in conditions that increased PAI-1 and approximated to those used for migration and invasion assays (ie pretreatment with G17, 1nM, 18h) there was no change in the adhesion response compared with acute stimulation suggesting that gastrin does not stimulate migratory and invasion responses as a consequence of long term changes in cell adhesion (Fig. 5) .
To address the significance of gastrin-stimulated PAI-1 expression in AGS-G R cell motility, we used siRNA to depress PAI-1 expression. After treatment with siRNA, gastrin-stimulated increases in PAI-1 mRNA abundance were virtually abolished (Fig. 6A ). There was also substantial reduction in PAI-1 detected by
Western blot, but no change in GAPDH abundance indicating the specificity of the knockdown (Fig. 6B ). In cells with PAI-1 knockdown, there were no differences in basal rates of migration and invasion. However there was significantly increased migration and invasion in response to an optimal concentration of G17 compared with cells treated with control siRNA (Fig.   7A,B) . The expression of PAI-1 in cancer, including gastric cancer, is associated with poor prognosis (3; 9; 16; 17). This is sometimes referred to as paradoxical given that uPA is also associated with poor prognosis and it might be expected that inhibition of uPA by PAI-1 would be beneficial. However, it is recognised that PAI-1 has both uPA dependent and independent effects, and that it can exert different actions with both beneficial and adverse consequences (21). 
